Helicobacter Pylori Clinical Trial
Official title:
A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With TAK-438 Versus Quadruple Therapy With Lansoprazole
To evaluate the safety, tolerability, and pharmacokinetics (PK) of quadruple therapy with bismuth, clarithromycin, amoxicillin, and TAK-438 versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and lansoprazole.
This is a phase 1, double-blind, parallel group study in participants with Helicobacter
pylori (HP positive) who are, additionally, cytochrome P-450 (CYP)2C19 extensive metabolizers
(EM) to evaluate the safety, tolerability and pharmacokinetics (PK) of a quadruple therapy
with bismuth, clarithromycin, amoxicillin, and TAK-438 versus quadruple therapy with bismuth,
clarithromycin, amoxicillin, and lansoprazole. The study will enroll 30 participants.
The treatment phase consists of quadruple therapy twice daily (BID) with tripotassium bismuth
dicitrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg), and TAK-438 (20 mg)
(Group B) or quadruple therapy BID with tripotassium bismuth dicitrate (600 mg),
clarithromycin (500 mg), amoxicillin (1000 mg),and lansoprazole (30 mg) (Group A) from Days 1
to 14. Participants will be discharged on Day 15 after final PK blood samples are collected
and all procedures performed.
This single-center will be conducted in Korea. Participants will remain confined to the study
site from check-in (Day -1) through Day 15 and will followed up through call on Day 17 and
return on Day 42 for a follow-up assessment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05073367 -
A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China
|
||
Completed |
NCT00596401 -
The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
|
||
Not yet recruiting |
NCT04101708 -
A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT04030715 -
The Associations Between the Gastric Mucosal Pathology and the Eradication Rate of H.Pylori :A Multicenter Study
|
N/A | |
Recruiting |
NCT04029493 -
The Situation of Re-infection of Helicobacter Pylori After Successful Eradication
|
||
Recruiting |
NCT04029415 -
The Study of the Antimicrobial Resistance of Helicobacter Pylori in Shandong Province
|
||
Not yet recruiting |
NCT02934048 -
Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection
|
Phase 4 | |
Not yet recruiting |
NCT02933229 -
The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study
|
Phase 4 | |
Recruiting |
NCT05184491 -
Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management
|
Phase 4 | |
Recruiting |
NCT05790525 -
Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy
|
Phase 4 | |
Completed |
NCT05790512 -
Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection
|
||
Recruiting |
NCT05276557 -
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
|
Phase 3 | |
Recruiting |
NCT03177629 -
H. Pylori Eradication for Moderate ITP
|
Phase 3 | |
Recruiting |
NCT05053945 -
Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
|
||
Recruiting |
NCT05449028 -
Helicobacter Pylori Eradication Therapy in Portugal
|
N/A | |
Recruiting |
NCT00306280 -
Feasibility Study of Phototherapy System to Treat H Pylori
|
N/A | |
Active, not recruiting |
NCT02675010 -
Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Study
|
N/A | |
Withdrawn |
NCT00467155 -
Helicobacter in The Gambia (Part 2)
|
N/A | |
Completed |
NCT03716622 -
A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication
|
Phase 4 | |
Not yet recruiting |
NCT04937426 -
Development of a Laboratory Test for the Detection of a Fluorescent-labeled Urease Inhibitor Marker Attached to Helicobacter Pylori
|
N/A |